Bavarian Nordic — Juni 2020
-
Zealand Pharma skal være med til at udvikle platform for Intomics
Zealand Pharma og Intomics skal sammen udvikle dataplatformen Inbio Discover. Det sker via et researchsamarbejde, oplyser Zealand Pharma onsdag morgen.
Samarbejdet skal gøre det nemmere for det danske selskab at bruge big data, kunstig intelligens og maskinlæring i opdagelsen og udviklingen af den næste generation af peptider som lægemidler.
-
- Vi fortsætter med at forbedre Zealand Pharmas muligheder inden for integrationen af big data med integration og analyse, og denne forskningsaftale vil styrke denne indsats yderligere, siger Rie Schultz Hansen, direktør og chef for Discovery and Innovation hos Zealand Pharma, i en meddelelse om samarbejdet.
Aftalen er toårig.
/ritzau/FINANS
-
CEO Emmanuel Dulac and CFO Matt Dallas will also participate in the 41st Annual Goldman Sachs Global Healthcare Conference held as a virtual event June 9-11, 2020. A company presentation is planned for June 11, 2020 at 10:30 AM Eastern. For more information, please refer to the event website at http://www.goldmansachs.com/gsevents/hcc2020.
-
-
Pga partnerskab Expres2ion / Bavarian Nordic
-
-
Bavarian får Ebolavaccineordre på $13.9 mio fra Janssen http://www.bavarian-nordic.com/investor/news/news.aspx?news=6062
-
Test.
-
Zealand Pharma presents clinical and non-clinical evidence for dasiglucagon rescue therapy at the 80th Scientific Sessions of the American Diabetes Association
Zealand Pharma presents clinical and non-clinical evidence for dasiglucagon rescue therapy at the 80th Scientific Sessions of the American Diabetes Association
Press release – No. 09 / 2020 Zealand Pharma presents clinical and non-clinical evidence for dasiglucagon rescue therapy at the 80th Scientific...
GlobeNewswire News Room (www.globenewswire.com)
-
Zealand Pharma presents elaborated results on the use of regular human insulin delivered by V-Go
in older adults with type 2 diabetes, at the 80th Scientific Sessions of the American Diabetes AssociationZealand Pharma presents clinical and non-clinical evidence for dasiglucagon rescue therapy at the 80th Scientific Sessions of the American Diabetes Association
Press release – No. 09 / 2020 Zealand Pharma presents clinical and non-clinical evidence for dasiglucagon rescue therapy at the 80th Scientific...
GlobeNewswire News Room (www.globenewswire.com)
-
ZEALAND PHARMA - NY LEDELSE I USA
https://www.proinvestor.com/debat/84684 -
Zealand Pharma udnævner direktør for USA
Zealand Pharma har udpeget Frank Sanders til jobbet som direktør for selskabets amerikanske forretning, oplyser selskabet i en meddelelse.
Sanders kommer fra en stilling som daglig leder af de kommercielle aktiviteter hos Sage Therapeutics.
-
I første omgang venter Zealand på markedsføringstilladelse til nødpennen Dasiglucagon Hypopal til diabetikere, der oplever alvorlige episoder af for lavt blodsukker.
Jefferies har tidligere estimeret et topsalg af pennen på 220 mio. dollar, eller op mod 1,5 mia. kr.
/ritzau/FINANS
-
Zealand Pharma announces directed issues and private placements of up to approx. 2.68 million new ordinary shares
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind